Abstract
Gold nanoparticles can be conjugated with antibodies or other proteins, and the resulting composite particles will selectively attach to various kinds of biological material. Although exploitation of this for staining microscopy specimens is well known, there has recently been interest in attaching gold nanoparticles tolive cells for therapeutic reasons. One motivation is that gold nanoparticles display a strong plasmon resonance with light, which can be exploited in principle for an ‘in vivo’ photothermal therapy. The treatment of cancer by this technique has recently received attention by others, but here we show how gold nanoparticlebased therapies can be developed to target live macrophage cells. We have employed ‘active targeting’, a scheme in which gold nanoparticles are functionalised with an antibody specific to the target macrophage cell. We describe how to prepare the conjugated particles, demonstrate that they will selectively attach ‘in vitro’ to their target macrophage cell but not to a non-target cell type and show that their presence renders the target cell susceptible to destruction by a low power laser.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
W. R. Glomm,J. of Dispersion Sci. and Technol., 2005,26, 389
W. P. Faulk & G. Taylor,Immunochem., 1971,8, 1081
M. A. Hayat. Colloidal Gold: Principles, Methods, and Applications (Academic Press, San Diego, CA, 1989)
S.- Y. Lin, S.-H. Wu & C.-H. Chen,Angew. Chem. Int. Ed., 2006,45, 4948
R. Elghanian, J. J. Storhoff, R. C. Mucic, R. L. Letsinger & C. A. Mirkin,Sci., 1997,277, 1078
C. R. Martin & D. T. Mitchell,Anal. Chem. News & Features, 1998,1st May, 322A
D. G. Richards, D. L. McMillin, E. A. Mein & C. D. Nelson,Intern. J. Neuroscience, 2002,112, 31
Z. Huaizhi & N. Yuantao,Gold Bull., 2001,34, 24
M.-C. Daniel & D. Astruc,Chem. Rev., 2004,104, 293
C. F. Shaw,Chem Rev., 1999,99, 2589
R. Eisler,Inflammation Research, 2003,52, 487
H. E. Harding,J. Clin. Path., 1953,6, 149
G. F. Paciotti et al.,Drug Delivery, 2004,11, 169
J. F. Hainfeld, D. N. Slatkin & H. M. Smilowitz,Phys. Med. Biol., 2004,49, N309-N315
J. F. Hainfeld & R. D. Powell,J. Histo. Cyto., 2000,48, 471
R.-Q. Liang et al.,Nucl. Acids Res., 2005,33, e17
R. Fernandes, K. Suzuki & A. K. Kumagai,IOVS, 2003,44, 3150
S. Chah, M. R. Hammond & R. N. Zare,Chem. & Biol., 2005,12, 323
D. J. Maxwell, J. R. Taylor & S. Nie,J. Am. Chem.Soc., 2002,124, 9606
C.-X. Lei, F.-C. Gong, G.-L. Shen & R.-Q. Yu,Sens. Act. B, 2003,96, 582–588
A. T. A. Jenkins, R. French-constant, A. Buckling, D. J. Clarke & K. Jarvis,Biotechnol. Prog., 2004,20, 1233
H. Wang et al.,Biosens. Bioelec., 2004,19, 701
C. Loo et al.,Technol. in Cancer Res. & Treatment, 2004,3, 33
B. Wiley et al.,MRS Bulletin, 2005,30, 356
D. Pissuwan, S. Valenzuela & M. B. Cortie,Trends Biotechnol., 2006,24, 62
C.-C. Chen et al.,J. Am. Chem. Soc., 2006,128, 3709
H. Takahashi, T. Niidome, A. Nariai, Y. Niidome & S. Yamada,Chem. Lett., 2006,35, 500
H. Takahashi, Y. Niidome & S. Yamada,Chem. Commun., 2005, 2247
I. H. El-Sayed, X. Huang & M. A. El-Sayed,Cancer Lett., 2006,239, 129
I. H. El-Sayed, X. Huang & M. A. El-Sayed,Nano Lett., 2005,5, 829
X. Huang, I. H. El-Sayed, W. Qian & M. A. El-Sayed,J. Am. Chem. Soc., 2006,128, 2115
Z. Krpetic, F. Porta & G. Scarì,Gold Bull., 2006,39, 66
S. E. McNeil,J. Leukoc. Biol., 2005,78, 585–594
S. M. Moghimi, A. C. Hunter & J. C. Murray,FASEB J., 2005,19, 311
B. D. Chithrani, A. A. Ghazani & W. C. W. Chan,Nano Lett., 2006,6, 662
R. Shukla et al.,Langmuir, 2005,21, 10644
V. P. Zharov, K. E. Mercer, E. N. Galitovskaya & M. S. Smeltzer,Biophys. J., 2006,90, 619
D. Lapotko et al.,Proceedings of SPIE, 2005,5697, 82
J. W. Slot & H. J. Geuze,Eur. J. Cell Biol., 1985,38, 87
S. H. Brewer, W. R. Glomm, M. C. Johnson, M. K. Knag & S. Franzen,Langmuir, 2005,21, 9303
C. De Roe, P. J. Courtoy & P. Baudhuin,J. Histochem. Cytochem., 1987,35, 1191
K. Rezwan, L. P. Meier & L. J. Gauckler,Biomaterials, 2005,26, 4351
D. P. O'Neal, L. R. Hirsch, N. J. Halas, J. D. Payne & J. L. West,Cancer Lett., 2004,209, 171
L. R. Hirsch, J. B. Jackson, A. Lee, N. J. Halas & J. L. West,Anal. Chem., 2003,75, 2377
C. M. Pitsillides, E. K. Joe, X. Wei, R. R. Anderson & C. P. Lin,Biophys. J., 2003,84, 4023
S. Link & M. A. El-Sayed,Inter. Rev. Phys. Chem., 2000,19, 409
D. O. Lapotko & V. P. Zharov,Lasers Surg. Med., 2005,36, 22
X. Huang, P. K. Jain, I. H. El-Sayed & M. A. El-Sayed,Photochem. Photobiol., 2006,82, 412
O. Salata,J. Nanobiotechnology, 2004,2, 3 doi:10.1186/1477
C. Yao et al.,J. Biomed. Optics, 2005,10, 064012
Author information
Authors and Affiliations
Corresponding author
Additional information
Ms Dakrong Pissuwan holds degrees from Srinakharinwirote University and King Mongkut's University of Technology Thonburi, both in Thailand. She is currently a PhD student at the University of Technology Sydney, Australia. Her research is directed towards developing antibody-targeting of gold nanoparticles for possible therapeutic applications.
Mr Colin Cortie is a biological sciences student in the Faculty of Science at the University of Wollongong, Australia. His contribution to the current work arose in the course of a vacation work project on gold nanoparticle-antibody conjugation conducted at the University of Technology, Sydney.
Dr Stella M. Valenzuela is a Lecturer in the Department of Medical and Molecular Biosciences at the University of Technology Sydney, Australia. She is a graduate of the Universities of New South Wales and Sydney, Australia. Her research interest is the structure and function of membrane proteins, with a particular focus on CLIC ion channel proteins.
Prof. Michael Cortie is the Director of the Institute for Nanoscale Technology at the University of Technology Sydney. The Institute specialises in the optical properties of materials at the nanoscale, and in precious metals nanotechnology. Michael is a graduate of the Universities of Witwatersrand and Pretoria, in South Africa but now resides in Australia.
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Pissuwan, D., Cortie, C., Valenzuela, S. et al. Gold nanosphere-antibody conjugates for hyperthermal therapeutic applications. Gold Bull 40, 121–129 (2007). https://doi.org/10.1007/BF03215568
Issue Date:
DOI: https://doi.org/10.1007/BF03215568